SUPPORTING INFORMATION
Supplemental Figure S1. The HRAS and BRAF detected mutations in the RMS patient.
Supplemental Figure S2. IGV of the detected mutations.
Supplemental Figure S3. Percent frequency of co-occurrence of HRAS mutations with BRAF classes I, II and III in cBioportal.
Supplemental Figure S4. Diagram of Class I, II and III BRAF mutations and the possible CLASS III inhibitors.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

## ACKNOWLEDGMENTS

Funding This work was supported by grants from Qatar National Research Fund (QNRF grant
PPM 05-0316-210001)

## AUTHORS CONTRIBUTION

S.S. Processed the WES data, collected the public data, performed the bioinformatic analysis and drafted the manuscript. W.H. Supervised the WES bioinformatic processing pipelines. C.R. extracted the DNA. A.M. Collected the clinical data. C.R. W.H., D.B., A.M., and W.M. participated in the interpretation of the results.